ArticleFrontiers in oncology2026
Durable progression-free survival with first-line sintilimab plus chemotherapy followed by sintilimab maintenance in PD-L1-high recurrent cervical cancer: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent advanced cervical cancer has an extremely poor prognosis, with a 5-year survival rate of only 20%. Cervical cancer is closely linked to persistent infection with high-risk Human papillomavirus and its tumor microenvironment is often enriched with immune cell infiltrates, especially CD8+ T cells, indicating a degree of immunogenicity. Immunotherapy can prolong progression-free survival and overall survival in a subset of these patients, with the greatest benefit observed in those with programmed death-ligand 1positive tumors or squamous cell histology. Sintilimab is a fully human IgG4κ anti-PD-1 monoclonal antibody that has yielded positive results in lymphomas and several advanced solid tumors. However, published data on its use as a first-line therapy for recurrent advanced cervical cancer remain scarce. Case presentation: We report a case involving a 51-year-old Chinese woman whose advanced cervical cancer recurred with bilateral lung metastases 3 years after radical surgery and radiotherapy. First-line treatment with sintilimab plus chemotherapy, followed by maintenance therapy with sintilimab, achieved a complete response and progression-free survival of 37.5 months. Only grade 2 or lower immune-related adverse events occurred: grade 1 subclinical hyperthyroidism and grade 2 leukopenia. Conclusions: Maintenance therapy with sintilimab after first-line treatment with sintilimab plus chemotherapy can confer substantial clinical benefits in patients with recurrent advanced cervical cancer, with a favorable safety profile and no serious adverse events observed, warranting further prospective investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.